Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2015-01-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD010533.pub2PMID 25572491PMCID PMC11064763
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

  2014cited by this paper
• Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.

  2014cited by this paper
• High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.

  2013cited by this paper
• AHL 2011: A Lysa randomized phase III study of a treatment driven by early PET response compared to a standard treatment in patients with Ann Arbor stage III-IV or high-risk IIB Hodgkin lymphoma.

  2013cited by this paper
• Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

  2012cited by this paper
• Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

  2012cited by this paper
• Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

  2012cited by this paper
• Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone

  2012cited by this paper
• Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma

  2012cited by this paper
• Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.

  2011cited by this paper
• Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

  2011cited by this paper
• Chapter 10: Addressing reporting biases

  2011cited by this paper
• The role of PET in Hodgkin’s lymphoma and its impact on radiation oncology

  2010cited by this paper
• Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma

  2010cited by this paper
• Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

  2010cited by this paper
• Incidence Patterns and Outcomes for Hodgkin Lymphoma Patients in the United States

  2010cited by this paper
• Clinical Manifestations and Natural History of Hodgkin’s Lymphoma

  2009cited by this paper
• FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value.

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

  2009cited by this paper
• FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

  2009cited by this paper
• Chapter 9: Analysing Data and Undertaking Meta-Analyses

  2008cited by this paper
• Chapter 8: Assessing risk of bias in included studies

  2008cited by this paper
• Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

  2008cited by this paper
• Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.

  2008cited by this paper
• Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

  2007cited by this paper
• Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

  2007cited by this paper
• Practical methods for incorporating summary time-to-event data into meta-analysis

  2007cited by this paper
• Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans

  2007cited by this paper
• Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features.

  2007cited by this paper
• FDG-PET scan and treatment planning for early stage Hodgkin lymphoma.

  2007cited by this paper
• First-line treatment of Hodgkin’s lymphoma

  2006cited by this paper
• First-line treatment of Hodgkin's lymphoma.

  2005cited by this paper
• From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential.

  2005cited by this paper
• Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

  2003cited by this paper
• Epidemiology and etiology of Hodgkin's lymphoma.

  2002cited by this paper
• Hodgkin's lymphoma: the pathologist's viewpoint.

  2002cited by this paper
• Hodgkin's lymphomas: classification, diagnosis, and grading.

  1999cited by this paper
• Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

  1998cited by this paper
• [Hodgkin's disease].

  1996cited by this paper
• Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

  1992cited by this paper
• Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

  1989cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper

• Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma.

  2025cites this paper
• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.

  2024cites this paper
• Pet-radiomics in lymphoma and multiple myeloma: update of current literature

  2023cites this paper
• Evidence-based Positron Emission Tomography: Summary of Recent Meta-analyses on PET

  2020cites this paper
• Relapsing/refractory HL after autotransplantation: which treatment?

  2020cites this paper
• PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma

  2020cites this paper
• TRIZ Theory and the Method of Cancer Document Selection for Chemical Complexes and Innovation Schemes of Meta-Analysis with Lymphomas as an Example

  2020cites this paper
• Evidence-Based PET for Haematological Tumours

  2020cites this paper
• Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

  2019cites this paper
• Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

  2019cites this paper
• Personalized medicine: From diagnostic to adaptive

  2019cites this paper
• Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab

  2019cites this paper
• [Hodgkin lymphoma: Current and future therapeutic strategies].

  2018cites this paper
• Interim PET Response‐adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric Trial

  2018cites this paper
• [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives

  2018cites this paper
• PET-adapted therapy for advanced Hodgkin lymphoma – systematic review

  2018cites this paper
• Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.

  2018cites this paper
• Hodgkin Lymphoma in Adults.

  2018cites this paper
• A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer

  2018cites this paper
• Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review

  2017cites this paper
• The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database

  2017cites this paper
• Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT

  2017cites this paper
• Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.

  2017cites this paper
• [New therapy outlooks in Hodgkin lymphoma].

  2017cites this paper
• Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.

  2017cites this paper
• Sunday 22 October 2017

  2017cites this paper
• Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy

  2016cites this paper
• Hodgkin lymphoma: a negative interim‐PET cannot circumvent the need for end‐of‐treatment‐PET evaluation

  2016cites this paper
• Health policy: Affordability of drugs used in oncology health care

  2016cites this paper
• PET-CT在霍奇金淋巴瘤临床应用中的进展及思考

  2016cites this paper
• Fluorine‐18‐fluorodeoxyglucose positron emission tomography/computed tomography (18F‐FDG‐PET/CT) for detecting metastases of Ewing sarcoma

  2016cites this paper
• PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma-a systematic review and meta-analysis.

  2016cites this paper
• Cochrane review: The Cochrane Database of Systematic Reviews—Issue 1 2015

  2015cites this paper
• How does positron emission tomography‐adapted therapy as first‐line treatment affect outcomes in people with early‐stage Hodgkin lymphoma?

  2015cites this paper
• Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging

  2015cites this paper
• Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas

  2015cites this paper
• Involved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adults

  2015cites this paper